Edition:
United Kingdom

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

10.72EUR
19 Jul 2019
Change (% chg)

€-0.10 (-0.92%)
Prev Close
€10.82
Open
€10.82
Day's High
€10.90
Day's Low
€10.60
Volume
167,525
Avg. Vol
96,532
52-wk High
€12.80
52-wk Low
€9.67

Latest Key Developments (Source: Significant Developments)

Biocartis And Kite Sign Agreement For Development Of Assays Supporting Kite's Therapies
Saturday, 1 Jun 2019 

June 1 (Reuters) - Biocartis Group NV ::BIOCARTIS GROUP NV SAYS BIOCARTIS AND KITE SIGN AGREEMENT FOR DEVELOPMENT OF ASSAYS SUPPORTING KITE'S THERAPIES.BIOCARTIS GROUP NV SAYS FINANCIAL DETAILS ON AGREEMENT WITH KITE ARE NOT DISCLOSED..  Full Article

Biocartis Announces Placement Of Senior Unsecured Convertible Bonds
Thursday, 2 May 2019 

May 2 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS ANNOUNCES SUCCESSFUL PLACEMENT OF EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024.BONDS SHALL BEAR A COUPON OF 4.00% PER ANNUM.CONVERSION PRICE WILL BE SET AT A 25.00% PREMIUM ABOVE REFERENCE PRICE.CLOSING AND SETTLEMENT OF THE OFFERING ARE EXPECTED TO OCCUR ON 9 MAY 2019.  Full Article

Biocartis Group Launches Convertible Bonds Offering Of 125 Million Euros
Thursday, 2 May 2019 

May 2 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES CONVERTIBLE BONDS OFFERING OF EUR 125 MILLION.BONDS WILL BE ISSUED AT 100% OF THEIR PRINCIPAL AMOUNT AND ARE EXPECTED TO BEAR A COUPON OF BETWEEN 3.375% AND 4.125% PER ANNUM, PAYABLE SEMI-ANNUALLY IN ARREAR.CLOSING AND SETTLEMENT OF OFFERING ARE EXPECTED TO TAKE PLACE ON OR AROUND 9 MAY 2019.LAUNCH OF AN OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024.COMPANY WILL AGREE TO A LOCK-UP UNDERTAKING IN RELATION TO ITS SHARES AND EQUITY-LINKED SECURITIES FOR A PERIOD ENDING 90 CALENDAR DAYS AFTER CLOSING DATE.CONVERSION PRICE EXPECTED AT PREMIUM BETWEEN 22.5% AND 27.5% ABOVE VOLUME WEIGHTED AVERAGE PRICE OF CO'S ORDINARY SHARE ON EURONEXT BRUSSELS FROM MARKET OPEN TO CLOSE OF TRADING ON LAUNCH DAY.LAUNCH OF AN OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS FOR INITIAL AGGREGATE PRINCIPAL AMOUNT OF EUR 125 MILLION WITH INCREASE OPTION OF UP TO EUR 25 MILLION.  Full Article

Biocartis Group Reiterates FY 2019 Guidance
Thursday, 25 Apr 2019 

April 25 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS Q1 2019 BUSINESS UPDATE.FULL YEAR 2019 GUIDANCE REITERATED.CASH POSITION: BIOCARTIS' CASH POSITION AT END OF Q1 2019 AMOUNTED TO EUR 100M (UNAUDITED FIGURE)..EQUITY RAISE: SUCCESSFUL EUR 55.5M PRIVATE PLACEMENT OF NEW SHARES ON 23 JANUARY 2019.AN ACCELERATED RAMP-UP OF US CARTRIDGE VOLUMES IS EXPECTED IN Q2 AND Q3 2019."WE STARTED 2019 WITH A GOOD FIRST QUARTER IN WHICH WE MADE PROGRESS ON ALL FRONTS: COMMERCIALIZATION, MENU EXPANSION, MANUFACTURING, FINANCING AND ORGANIZATION," CEO.  Full Article

Biocartis And Bristol-Myers Squibb Sign Agreement For MSI Testing With Immuno-Oncology Therapies
Tuesday, 12 Mar 2019 

March 12 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS AND BRISTOL-MYERS SQUIBB SIGN COLLABORATION AGREEMENT FOR MSI TESTING WITH IMMUNO-ONCOLOGY THERAPIES.  Full Article

Biocartis Group Launches Equity Placement
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT.ANNOUNCES TODAY LAUNCH OF AN EQUITY OFFERING TO RAISE AN AMOUNT OF APPROXIMATELY EUR 45 MILLION BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING.ACCELERATED BOOKBUILDING PROCEDURE WILL COMMENCE IMMEDIATELY.TRADING IN STOCK IS EXPECTED TO RESUME FOLLOWING PUBLICATION OF RESULTS OF OFFERING.TRADING IN BIOCARTIS SHARES ON EURONEXT BRUSSELS WILL BE SUSPENDED DURING BOOKBUILDING PERIOD.  Full Article

Biocartis Group Q3 Cash Position at 81 Million Euros
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - BIOCARTIS GROUP NV ::CASH POSITION: BIOCARTIS' CASH POSITION AT END OF Q3 2018 AMOUNTED TO EUR 81M (UNAUDITED FIGURE).  Full Article

Biocartis H1 Net Loss Narrows To 21.8 Million Euros
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - BIOCARTIS GROUP NV ::H1 TOTAL OPERATING INCOME EUR 12.74 MILLION VERSUS EUR 7.0 MILLION YEAR AGO.H1 NET LOSS EUR 21.8 MILLION VERSUS LOSS OF EUR 24.0 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS OF EUR 91.3 MILLION AS PER END H1 2018.H1 OPERATIONAL LOSS EUR 21.1 MILLION VERSUS LOSS OF EUR 23.7 MILLION YEAR AGO.LAUNCH OF IDYLLA(TM) CTESR1 (RUO) ASSAY, WHICH IS DEVELOPED IN COLLABORATION WITH LIFEARC, IS NOW SET FOR 2019.  Full Article

Biocartis Group Cash Position At End Q1 2018 Was 102 Million Euros
Thursday, 26 Apr 2018 

April 26 (Reuters) - Biocartis Group NV ::CASH POSITION AT END OF Q1 2018 AMOUNTED TO EUR 102M (UNAUDITED FIGURE).FULL YEAR GUIDANCE REITERATED.  Full Article

Biocartis FY Total Operating Income Up At 23.1 Million Euros
Thursday, 1 Mar 2018 

March 1 (Reuters) - Biocartis Group Nv ::FY TOTAL OPERATING INCOME: EQUALED EUR 23.1M IN 2017 COMPARED TO EUR 13.8M IN 2016,.CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 112.8M AS PER 31 DECEMBER 2017.EXPECTS CASH POSITION IN THE RANGE OF EUR 50MLN – EUR 60MLN BY 2018 YEAR END.FY NET LOSS EUR 42 MILLION VERSUS LOSS OF EUR 49.8 MILLION.FY OPERATING LOSS EUR 43.6 MILLION VERSUS LOSS EUR 50.2 MILLION YEAR AGO.  Full Article